Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Aerodynamic and Flexible Trucks for Next Generation of Long Distance Road Transport (AEROFLEX)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Action type: Innovation actions
Partnership: EGVI (cPPP)
Countries involved: Germany,Austria,Germany,Spain,Italy,Germany,Germany,Sweden,Türkiye,Belgium,Sweden,Sweden,Belgium,France,Netherlands,Netherlands,Netherlands,Netherlands,Netherlands,Netherlands,Netherlands
Call: Aerodynamic and flexible trucks (H2020-GV-2017, 2017)
Start date: 2017-10-01
End date: 2021-09-30
Duration (months): 48.0
Total project cost (EUR): 11818561.25
EU funding (EUR): 9534778.64
Participants: 27
Project status: CLOSED

The transport sector contributes to about 25% of total CO2 emissions in the EU and is the only sector where the trend is still increasing. Taking into account the growing demand on the road transport system and the ambitious targets of the EC’s Transport White Paper, it is paramount to increase the efficiency of freight transport. The vision of the AEROFLEX project is to support vehicle manufacturers and the logistics industry to achieve the coming challenges for road transport. The overall objective of the AEROFLEX project is to develop and demonstrate new technologies, concepts and architectures for complete vehicles with optimised aerodynamics, powertrains and safety systems as well as flexible and adaptable loading units with advanced interconnectedness contributing to the vision of a “physical internet”. The optimal matching of novel vehicle concepts and infrastructures is highly important, requiring the definition of smart infrastructure access policies for the next generation of trucks, load carriers and road infrastructure. The specific technical objectives, main innovations and targeted key results are: 1. Characterise the European freight transport market (map, quantify and predict), the drivers, the constraints, the trends, and the mode and vehicle choice criteria 2. Develop new concepts and technologies for trucks with reduced drag, which are safer, comfortable, configurable and cost effective and ensure satisfaction of intermodal customer needs under varying transport tasks and conditions. 3. Demonstrate potential truck aerodynamics and energy management improvements with associated impact assessments of the new vehicle concepts, technologies and features developed in the AEROFLEX project. 4. Drafting of coherent recommendations for revising standards and legislative frameworks in order to allow the new aerodynamic and flexible vehicle concepts on the road. To achieve an overall 18-33% efficiency improvement in road transport / long haulage by 2025+.

Keywords: multi modality,combined transport,aerodynamics,energy management systems,distributed drive trains,wireless communication,smart loading units
Multidisciplinary European network for research, prevention and control of the COVID-19 Pandemic (I-MOVE-COVID-19)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: Research and Innovation actions
Countries involved: Spain,Ireland,Albania,Germany,Spain,Spain,Spain,Belgium,Lithuania,Romania,Sweden,France,France,France,France,France,France,Netherlands,United Kingdom,United Kingdom,United Kingdom,Portugal,United Kingdom,United Kingdom
Call: Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic (H2020-SC1-PHE-CORONAVIRUS-2020, 2020)
Start date: 2020-03-16
End date: 2022-06-15
Duration (months): 27.0
Total project cost (EUR): 2849428.32
EU funding (EUR): 2808162.5
Participants: 33
Project status: SIGNED

I-MOVE-COVID-19 aims to obtain epidemiological, clinical and virological information about COVID-19 and patients infected with SARS-CoV-2, through provision of a flexible surveillance platform (adaptable to the epidemiological situation), research studies, hypothesis-testing and evaluation of public health interventions (e.g. vaccination, antivirals) in order to contribute to the knowledge base, guide patient management, and inform the public health response. This will be achieved through adaptation and expansion of the existing, long-running, Europe-wide influenza surveillance network (I-MOVE) to include COVID-19. The network includes primary care networks, hospitals, national laboratory reference centres in eleven countries. I-MOVE-COVID-19 priority activities and research projects will be selected based on ECDC/WHO input and the proposal’s detailed list. These will be conducted by mobilising an existing large European multidisciplinary network, combining the expertise and resources of groups working in surveillance (epidemiological, clinical, virological), respiratory disease research, and evaluation of vaccines/treatments. Through protocol sharing and pooling European results, questions will be answered which could not be efficiently answered by countries acting alone. I-MOVE-COVID-19 will share study results rapidly and widely with national and international partners and with the wider scientific community and contribute to clinical management of patients and public health preparedness and response to COVID-19.

Keywords: primary care,hospital networks,pooled epidemiological studies,multidisciplinary network,epidemiological,clinical,virological surveillance,respiratory disease research,vaccines,treatment evaluation
First effective pharmacotherapy for ARDS to lower mortality and improve quality of life of patients. (Impentri)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: United Kingdom
Call: SME instrument (H2020-EIC-SMEInst-2018-2020-3, 2020)
Start date: 2020-10-01
End date: 2022-09-30
Duration (months): 24.0
Total project cost (EUR): 1798912.99
EU funding (EUR): 1259239.09
Participants: 1
Project status: CLOSED

Acute Respiratory Distress syndrome (ARDS) is a life threatening condition that affects 3 million people world-wide. With regards to the current coronavirus pandemic, ARDS is the immediate cause of death for patients suffering from this infection. 40% of the patients that suffer from the condition succumb to it and among the ones that survive, most of them face long-term physical and mental illness. The unreliable, costly, prolonged treatment options currently available are responsible for the high mortality observed in the condition. The treatments offer only relief from symptoms and manage the condition but are not curative. Exvastat is developing impentri as a reliable and effective pharmacotherapy for ARDS as it targets the cause and trigger of the mortality associated with the condition. It is an intravenous formulation of widely-used chemotherapeutic drug, Imatinib which has shown promising results in-vitro and clinical reports in ARDS like conditions. Being a repurposed drug, Impentri has the advantage of reaching human trials earlier than other drugs. With EIC funds Exvastat plans to register and successfully finish 50% of the PhaseII trials in ARDS patients. This would provide an opening for the drug to successfully finish further trials and its orphan drug status would guarantee early market entry. With Impentri Exvastat wants to lower mortality and provide better quality of life to patients suffering from ARDS

Keywords: coronavirus,covid19,covid 19,acute respiratory distress syndrome,sepsis,ventilation,imatinib,re purposed drug,orphan drug,intravenous administration
Households’ Consumption during the Great Recession: A structural analysis on the role of expectations (CONSCRISIS)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Economic Sciences
Countries involved: United Kingdom
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2014, 2014)
Start date: 2015-11-01
End date: 2017-10-31
Duration (months): 24.0
Total project cost (EUR): 183454.8
EU funding (EUR): 183454.8
Participants: 1
Project status: CLOSED

A striking feature of the Great Recession is the fall in households’ expenditure and its slow recovery. The extraordinary duration of this contraction with respect to previous recessions stimulated the interest of scholars and policymakers in the analysis of its causes. In the early part of the crisis it is partly explained by a sudden crash in asset values. More recently, the decline in consumer confidence in several European countries is likely to have played a major role. This project aims to explore which factors explain why consumption has moved following the crisis and to assess the relevance of downwards revisions of income expectations. Households who experience a deep and prolonged period of economic downturn, such as the Great Recession, may become increasingly convinced about the permanence of income shocks over time. Gradual downwards revisions of expectations about permanent income are likely to lead to a series of downwards adjustments in consumption spending. This project will exploit a structural approach that will enable me to investigate the relevance for consumption of this process of adjustment. The contribution of this proposal is threefold. First, it improves the understanding of households’ consumption choices by analysing the role of income expectations. Second, it adds to the literature that investigates the determinants of the recession. The third contribution is methodological. An integral part of the project will be the elaboration and numerical solution of a lifecycle consumption-savings model with the novel feature that agents cannot (fully) observe the nature of the income shock and, thus, need time to learn about its permanence. The relevance of this proposal in a European perspective is enhanced by the cross-country perspective of the empirical analysis. The outstanding experts in Econometrics, Economics of Consumption and, more precisely, in the use of structural models, make UCL the perfect environment to carry out this project.

Keywords: households consumption,financial crisis,expectations on future earnings,structural models
Metabolic Adaptation and Resilience in the face of a changing environment (MARY)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: United Kingdom
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2022-08-22
End date: 2024-08-21
Duration (months): 24.0
Total project cost (EUR): 212933.76
EU funding (EUR): 212933.76
Participants: 1
Project status: SIGNED

Microbes have evolved to make the best use of their environmental resources while retaining sufficient adaptive capacity to cope with changing conditions. However, even simple changes in the environment require major cellular rearrangements, that manifest in the transcriptome, proteome and metabolome of the cell. For instance, a change in the availability of just four non-essential nutrients affects expression of 2/3rds of all yeast genes. In essence, we do not understand the key molecular mechanisms that govern such huge plasticity, which buffering mechanisms prevent the collapse of the cellular system, and how an optimal resource allocation is achieved to allow cells to thrive in so many environments. In this project, we will analyse a large collection of yeast wild isolates grown in conditions that resemble different ecological niches. We will identify the key molecular pathways that enable environmental adaption. Thanks to unique high-throughput capacities of the host laboratory, I will be able to record proteomes, metabolomes and growth properties of the wild yeast strains. I’ll link these molecular datasets to fitness and metabolism. My background being in big data analysis and network modelling, I will use genome-scale metabolic models and machine-learning to characterize how changes in protein resource allocation impact the distribution of metabolic flux in such context, and define, what are the regulatory mechanisms influencing metabolism at its different levels. Eventually, the knowledge gained will enable me to build a predictive model to understand the drivers of adaptations to ecological niche. By deepening our understanding of the mechanisms behind metabolic niche adaptation, this project will not only answer fundamental questions about the inner working of the cell but will also increase our ability to engineer yeast for biotechnological applications and to understand the problematic resilience of fungal pathogens to therapeutic interventions.

Keywords: metabolism,resilience,adaptation,regulatory network,omics,yeast,inter strain diversity,modelling,machine learning
Rapid Antimicrobial susceptibility testing and phylogenetic Identification (RAPID)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Germany
Call: ERC Proof of Concept Grant (ERC-2015-PoC, 2015)
Start date: 2016-10-01
End date: 2018-03-31
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

Emerging resistance towards antimicrobials marks this decade and the lack of therapy options especially against gram-negative pathogens underscores the need for optimization of current diagnostics, therapies and prevention of the spread of these organisms. In this proposal the PIs medical microbiology background and previous ERC-funded work on molecular resistance markers is exploited towards the development of a diagnostic assay for resistance profiling and genotyping. The implementation of the molecular StG-knowledge based RAPID (Rapid Antimicrobial susceptibility testing and Phylogenetic Identification) Assay could change the current paradigm of culture-based microbiological diagnostics and facilitate surveillance of multi-drug resistance. The overall objective is to initiate steps of pre-commercialization. Through the simultaneous pursuit of exploratory and exploitative innovation activities RAPID will be developed as a diagnostic tool for clinical microbiological laboratories. By applying our molecular assay in phase II diagnostic trials on a world-wide collection of multi-drug resistant pathogens, measures of diagnostic accuracy will be obtained. In addition to the assessment and critical appraisal of the diagnostic test, I will partner with the technology transfer company Ascenion, and apply for the CE label for RAPID. The CE mark will open the door for further commercialization opportunities such as licensing or offering the RAPID Assay as a service. In addition, market research, protection of intellectual property and contacts with end users and pharmaceutical industry for partnering activities will be central to the project. The implementation of RAPID as a tailored and cost-effective diagnostic tool in clinical microbiology laboratories holds promise to provide critical information for decision-making with respect to antibiotic use and for improvement of disease surveillance in multi-drug resistant nosocomial infections, and thus is of high priority.

Keywords: in vitro diagnostics,multi drug resistance,molecular diagnostics
Innovative environmentally-benign wastewater treatment reagents offering a step change in efficiency in the cleaning of water from oils and metal ions and in liquidation of emergency oil spills (BioMicroGels)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Nanotechnologies
Action type: SME instrument
Countries involved: Finland,United Kingdom
Call: Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2016-08-01
End date: 2016-12-31
Duration (months): 5.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 2
Project status: CLOSED

BioMicroGels (BMG) are an innovative versatile solution (1) for the removal of oil, oil products, lubes and greases as well as metal ions from domestic and industrial wastewater, and (2) for the clean-up of oil spills in water. BMG Intepco’s novel patented water cleaning microgel reagent is made of environmentally benign polysaccharides that are obtained from cellulose or pectin (found in apples, sunflowers and other bio-resources). BMG have a number of advantages over currently employed water treatment methods: (1) improved efficiency: rapid action and high water purity achievable within a single cleaning cycle with low reagent concentration (2) cost-efficiency: BMG cost comparatively lower and can be reused up to five times, besides, do not require expensive flocculants to form sediments; (3) enhance sustainability profile: bio-degradable; do not produce insoluble toxic slimes to dispose of (4) resource efficiency: collected oil and metals can be recovered For oil spills removal applications: (5) BMGs contain oil film spreading by converting oil to gel structure (up to 50 times reduction of oil spill area) (6) can be sprayed over surface oil spill or introduced under water (7) low freezing point (below -15-19°C) enables arctic environment applications (8) oil enveloped with BMG loses its flammable properties and does not adhere to birds, animals and other objects BMG solution addresses a global $5.5 bn market and would be of interest to (i) municipal wastewater treatment plants, (ii) various industrial companies (refineries, chemical, metals, mechanical, food and drink), (iii) shale oil and underwater oil development, oil and oil products transportation. The Phase 1 focuses on developing of a microgel technology application and conducting industrial trials as part of commercialisation, formulating sound business model and IP strategy, establishing a complete supply chains and developing an industrialisation plan for a large scale production process.

Keywords: wastewater treatment,water treatment,oil removal,metal ion removal,microgels,polysaccharides,oil spill response,oil recycling,water contamination,efficient treatment,environmentally friendly
LiveJourney (LiveJourney)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: SME instrument
Countries involved: France
Call: Open Disruptive Innovation Scheme (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2017-02-01
End date: 2017-07-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

In the on-demand digital era, time has become one of the most valuable commodities. Companies thrive or fail due to their process speed. This requires companies to track and optimize every step in their customers' "journey" - the chain of events that begins when a customer first interacts, and ends when the product or service is delivered or completed. Current solutions for LiveJourney are inadequate as they do not track or optimize time, and are difficult to install and integrate with existing systems. LiveJourney is a breakthrough SaaS solution that enables companies to track and optimize their customer journeys through a simple web dashboard. It uses real-time data visualizations and algorithms with complex process mining and statistical models. LiveJourney tracks and predicts journey time, can be used out-of-the-box even by non-technical staff, and is accessibly priced for any company. Early trials shows it can reduce journey times by 10-25%, predict journey duration with 82% accuracy, and increase customer retention by 8%. It is developed by Your Data Consulting, a French SME launched in April 2015 by five experienced founders. It has already developed and released a working beta version of its product, attracted five clients including major French brands, and earned €150K in revenue. It targets B2B customers including large enterprises in logistics, supply chains, finance, insurance and automobile manufacturing. It will scale up in France and expand to Germany, Italy, Spain, United Kingdom and United States, where there are 25,885 applicable companies and a TAM of over €1.1B. It reaches customers via direct sales and partner agents. By 2020 it will scale to 24 staff, achieve €7.4M in revenue, earn an EBIT of €2.01M. LiveJourney is now applying to undertake a Feasibility Study to prove technical and commercial viability and subsequently raise a larger funding round to fully commericalize its innovative product.

Keywords: customers journey,digital era,saas,optimization,disruptive innovation
BEHAVIOURAL ECOTOXIOCOLOGY MEETS CLIMATE CHANGE: Interactive effects of mercury pollution and climate change on behaviour, physiology and fitness in a keystone arctic seabird (BehavToxArc)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: France
Call: Individual Fellowships (H2020-MSCA-IF-2019, 2019)
Start date: 2020-07-01
End date: 2022-12-28
Duration (months): 24.0
Total project cost (EUR): 184707.84
EU funding (EUR): 184707.84
Participants: 1
Project status: SIGNED

The arctic marine biota is vulnerable to effects of climate change and anthropogenic contaminants. The artic is warming rapidly and is a sink for pollutants, including methylmercury (MeHg), which bioaccumulates in marine food chains. Ecotoxicological studies in the arctic have not adequately considered effects of contaminants on animal behaviour and fitness, or interactions between contaminants and climate change. This study (BehavToxArc) will address these urgent research areas using a keystone arctic seabird, the little auk (Alle alle). I will collect data from two colonies that are experiencing different environmental conditions and climate change impacts, and explore whether disruption of behaviour or stress physiology by Hg might limit adjustments to environmental change. I will use ultralight GPSs and accelerometers to collect unique behavioural data, which will be linked to state-of-the-art Hg measurements, and complemented by a long-term dataset (from accelerometers since 2009). I will also perform cutting-edge experiments to manipulate stress physiology, and explore cross-generational effects of Hg exposure in the context of climate change, focusing on telomeres. I will work with Dr. Jérôme Fort within the AMARE (Responses of Marine Organisms to Environmental Variability) group at La Rochelle University’s Institute Littoral Environnement et Sociétés. BehavToxArc will synthesize my expertise in behavioural ecotoxicology and telomere biology with Dr. Fort’s expertise in arctic ecotoxicology and spatial ecology. The project will introduce me to state-of-the art methods to monitor movement behaviour and measure telomeres, and the highly topical fields of arctic ecotoxicology and global change biology. Results will be disseminated by top-tier publications, conferences and public engagement, and used to advance scientific knowledge and environmental policy. The project will pivotally advance my career and propel me towards a permanent research position.

Keywords: arctic biology,global change biology,behavioral ecotoxicology,mercury pollution,animal personality,seabirds